Drugs / Rapamycin
Rapamycin
also known as
sirolimus · RAPA · Encapsulated Rapamycin · eRapa · PTX-022 · QTORIN · (RAPA, RapamuneR) (sirolimus) · Rapamune
Small molecule targets IL2, MTOR via inhibition
Trials 90 · started per year
today
1
1
2
1
2
5
7
6
6
2
3
3
3
2
4
5
4
5
2
2
3
7
1
3
5
3
20002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 08 trials | ||||||
| Phase 0 | NCT06658093 | Mar 2026 → Jul 2028 expected | — | The University of Texas Health Science Center at San Antonio | Recruiting | No outcome recorded |
| Phase 0 | NCT07354620 | Feb 2025 → Feb 2026 overdue | premature aging syndrome | The Christ Hospital | Active not recruiting | No outcome recorded |
| Phase 0 | NCT05532072 | Sep 2022 → Sep 2023 | disease of orbital part of eye adnexa | First Affiliated Hospital Xi'an Jiaotong University | Unknown | No outcome recorded |
| Phase 0 | NCT04049552 | Jan → Aug 2020 | keloid | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 0 | NCT02646319 | Jan 2016 → Sep 2017 | cervical squamous cell carcinoma, endometrial carcinoma, female breast carcinoma, head and neck carcinoma +5 | Mayo Clinic | Completed | No outcome recorded |
| Phase 0 | NCT01827618 | Apr 2012 → Apr 2014 | urinary bladder carcinoma | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 0 | NCT01396200 | Jun 2011 → Oct 2012 | plasma cell myeloma | Abramson Cancer Center at Penn Medicine | Completed | No outcome recorded |
| Phase 0 | NCT00583063 | Oct 2007 → Apr 2008 | cancer | University of Chicago | Completed | No outcome recorded |
| Phase 123 trials | ||||||
| Phase 1 | NCT07058974 | Aug 2025 → Jul 2026 overdue | — | Icahn School of Medicine at Mount Sinai | Recruiting | No outcome recorded |
| Phase 1 | NCT06743503 | Apr 2025 → May 2028 expected | large B-cell lymphoma | Nanjing IASO Biotechnology Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06528301 | Mar 2025 → Mar 2029 expected | B-cell chronic lymphocytic leukemia, diffuse large B-cell lymphoma | Umoja Biopharma | Recruiting | No outcome recorded |
| Phase 1 | NCT04994561 | Jun 2022 → Dec 2023 | — | Vitality in Aging Research Group, Inc. | Withdrawn | No outcome recorded |
| Phase 1 | NCT04996719 | May 2022 → Aug 2023 | heart failure | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT03618355 | Aug 2018 → Dec 2019 | prostate cancer | Rapamycin Holdings, Inc. dba Emtora Biosciences | Completed | No outcome recorded |
| Phase 1 | NCT01649960 | Aug 2012 → Dec 2015 | premature aging syndrome | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT01282697 | Apr 2011 → Feb 2013 | childhood malignant neoplasm | University Hospital, Strasbourg, France | Completed | No outcome recorded |
| Phase 1 | NCT00861874 | Jan 2010 → Sep 2012 | acute myeloid leukemia | University of Rochester | Completed | No outcome recorded |
| Phase 1 | NCT01031901 | Dec 2009 → Feb 2011 | neurofibroma, neurofibromatosis, tuberous sclerosis, vascular neoplasm | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 1 | NCT00830466 | Dec 2008 → Jan 2016 | capillary malformation | University of California, Irvine | Completed | No outcome recorded |
| Phase 1 | NCT00800722 | Nov 2008 → Jun 2014 | capillary malformation | University of California, Irvine | Completed | No outcome recorded |
| Phase 1 | NCT00667485 | Apr 2008 → May 2012 | cancer of unknown primary site, metastatic malignant neoplasm | University of Chicago | Completed | No outcome recorded |
| Phase 1 | NCT00555256 | Nov 2007 → Feb 2010 | non-small cell lung carcinoma | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT00525889 | Aug 2007 → Sep 2011 | type 1 diabetes mellitus | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00780104 | Jul 2007 → Jan 2010 | acute myeloid leukemia, chronic myeloid leukemia | Abramson Cancer Center at Penn Medicine | Completed | No outcome recorded |
| Phase 1 | NCT00901849 | May 2007 → Jul 2010 | low grade glioma | Roger Packer | Completed | No outcome recorded |
| Phase 1 | NCT00467194 | Dec 2006 → May 2011 | liver cancer | National Cancer Centre, Singapore | Completed | No outcome recorded |
| Phase 1 | NCT00449280 | Nov 2006 → Jun 2009 | cancer or benign tumor | University of Chicago | Completed | No outcome recorded |
| Phase 1 | NCT00375245 | Sep 2006 → May 2009 | metastatic neoplasm, neoplasm | University of Chicago | Completed | No outcome recorded |
| Phase 1 | NCT00402415 | Feb 2006 → Jul 2008 | neoplasm | Yale University | Terminated | No outcome recorded |
| Phase 1 | NCT00707135 | Jun 2005 → Sep 2008 | cancer of unknown primary site | University of Chicago | Completed | No outcome recorded |
| Phase 1 | NCT00708591 | Oct 2004 → Dec 2008 | cancer of unknown primary site | University of Chicago | Completed | No outcome recorded |
| Phase 1/210 trials | ||||||
| Phase 1/2 | NCT05605665 | Dec 2022 → Dec 2023 | Sjogren syndrome | Peking University People's Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT03383380 | Dec 2017 → Nov 2022 | activated PI3K-delta syndrome | Children's Hospital of Fudan University | Completed | No outcome recorded |
| Phase 1/2 | NCT03103893 | Sep → Nov 2017 | skin atrophy | Drexel University | Completed | No outcome recorded |
| Phase 1/2 | NCT01684449 | Jan 2010 → May 2013 | soft tissue sarcoma | Spanish Group for Research in Sarcomas | Completed | No outcome recorded |
| Phase 1/2 | NCT00623012 | Feb 2008 → Aug 2013 | graft versus host disease | Yale University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT00776373 | Jan 2007 → Dec 2008 | Burkitt lymphoma, chronic myeloid leukemia, precursor lymphoblastic lymphoma/leukemia | Abramson Cancer Center at Penn Medicine | Terminated | No outcome recorded |
| Phase 1/2 | NCT00409994 | Sep 2006 → Aug 2018 | rectal cancer | Maastricht Radiation Oncology | Completed | No outcome recorded |
| Phase 1/2 | NCT00311623 | Aug 2006 → Jan 2008 | prostate cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 1/2 | NCT00241189 | Aug 2002 → Jun 2006 | systemic sclerosis | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 1/2 | NCT00047073 | Jul 2002 → Jun 2005 | central nervous system neoplasm | Jonsson Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 225 trials · 2 met primary · 1 missed | ||||||
| Phase 2 | NCT06308445 | Sep 2026 → Sep 2030 expected | classic familial adenomatous polyposis | University Hospital, Toulouse | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07436611 | Aug 2026 → Oct 2027 expected | capillary malformation | AFT Pharmaceuticals, Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06563817 | Aug 2024 → May 2025 overdue | intracerebral hemorrhage, normal pressure hydrocephalus | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05836025 | Jun 2023 → Oct 2025 overdue | premature menopause | Columbia University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04742777 | Feb 2022 → Sep 2025 | — | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 2 | NCT04230499 | Jan 2021 → Mar 2025 overdue | classic familial adenomatous polyposis | Rapamycin Holdings Inc. | Active not recruiting | Met primary |
| Phase 2 | NCT04488601 | Jan 2020 → Dec 2023 | premature aging syndrome | AgelessRx | Completed | No outcome recorded |
| Phase 2 | NCT03243019 | Jun 2018 → Feb 2027 expected | lymphatic malformation | University Hospital, Lille | Recruiting | No outcome recorded |
| Phase 2 | NCT03161340 | Jul 2017 → May 2018 | infertility disorder | Mehdi Yousefi | Completed | No outcome recorded |
| Phase 2 | NCT02642094 | Jul 2016 → Mar 2022 | breast cancer | LuZhe Sun | Terminated | Mixed |
| Phase 2 | NCT02874924 | Jun 2016 → Sep 2018 | — | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 2 | NCT02803892 | May 2016 → Dec 2018 | type 1 diabetes mellitus | Piemonti Lorenzo | Completed | Missed primary |
| Phase 2 | NCT02596828 | Apr 2016 → Apr 2021 | pineoblastoma | University of Regensburg | Completed | No outcome recorded |
| Phase 2 | NCT02505893 | Apr 2015 → May 2018 | type 1 diabetes mellitus | Ospedale San Raffaele | Completed | No outcome recorded |
| Phase 2 | NCT01467986 | Aug 2013 → Sep 2020 | neuroblastoma | University of Regensburg | Completed | Met primary |
| Phase 2 | NCT02429973 | Jul 2012 → Dec 2014 | osteosarcoma | Broto, Javier Martín, M.D. | Completed | No outcome recorded |
| Phase 2 | NCT02080624 | Jan 2011 → Sep 2012 | Sturge-Weber syndrome | Clinica Universidad de Navarra, Universidad de Navarra | Completed | No outcome recorded |
| Phase 2 | NCT00779194 | Oct 2008 → Dec 2015 | systemic lupus erythematosus | State University of New York - Upstate Medical University | Completed | No outcome recorded |
| Phase 2 | NCT01014234 | Jul 2008 → Jun 2013 | — | Fondazione IRCCS Policlinico San Matteo di Pavia | Completed | No outcome recorded |
| Phase 2 | NCT00411788 | Dec 2006 → May 2010 | breast cancer | Yale University | Completed | No outcome recorded |
| Phase 2 | NCT00126672 | Dec 2005 → Apr 2010 | kidney angiomyolipoma, lymphangioleiomyomatosis, tuberous sclerosis | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT00276744 | Oct 2005 → Apr 2010 | malignant pancreatic neoplasm | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Terminated | No outcome recorded |
| Phase 2 | NCT00795886 | Aug 2005 → Mar 2010 | acute lymphoblastic leukemia | University of Utah | Completed | No outcome recorded |
| Phase 2 | NCT00235560 | Jun 2005 → Jun 2008 | acute myeloid leukemia | University Hospital, Toulouse | Completed | No outcome recorded |
| Phase 2 | NCT00533442 | Sep 2000 → May 2016 | type 1 diabetes mellitus | University of Miami | Completed | No outcome recorded |
| Phase 2/37 trials · 2 missed | ||||||
| Phase 2/3 | NCT07092618 | Dec 2024 → Aug 2025 overdue | — | AgelessRx | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04987463 | May 2021 → Mar 2026 | tuberous sclerosis | Katarzyna Kotulska | Unknown | No outcome recorded |
| Phase 2/3 | NCT03826628 | Jul 2019 → Sep 2022 | tuberous sclerosis, vascular neoplasm | Dermatology Specialties Limited Partnership | Completed | No outcome recorded |
| Phase 2/3 | NCT03920228 | Apr 2019 → Sep 2020 | pachyonychia congenita | Palvella Therapeutics, Inc. | Completed | Missed primary |
| Phase 2/3 | NCT04598204 | Dec 2017 → Dec 2022 | vascular malformation | Zhujiang Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT02481453 | Jul 2015 → Jan 2018 | inclusion body myositis | French National Institute of Health and Medical Research | Completed | Missed primary |
| Phase 2/3 | NCT00920309 | Jun 2009 → Jul 2010 | autosomal dominant polycystic kidney disease | Yale University | Terminated | No outcome recorded |
| Phase 38 trials · 2 met primary · 1 missed | ||||||
| Phase 3 | NCT07475546 | Jul 2025 → Apr 2026 overdue | — | AgelessRx | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06239480 | Jul 2024 → Jan 2026 overdue | microcystic lymphatic malformation | Palvella Therapeutics, Inc. | Active not recruiting | Met primary |
| Phase 3 | NCT05643872 | Nov 2022 → Oct 2023 overdue | pachyonychia congenita | Palvella Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT04736589 | Feb 2021 → Feb 2024 overdue | breast cancer | Peking Union Medical College | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT03140449 | Sep 2013 → Nov 2016 | benign vascular tumor | National Taiwan University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00928798 | Jan 2010 → Feb 2011 | Birt-Hogg-Dube syndrome | Maastricht University Medical Center | Completed | Missed primary |
| Phase 3 | NCT00133887 | Apr 2004 → Mar 2011 | skin cancer | Hospices Civils de Lyon | Completed | Met primary |
| Phase 3 | NCT01060605 | Oct 2001 → Dec 2005 | type 1 diabetes mellitus | IRCCS San Raffaele | Completed | No outcome recorded |
| Phase 45 trials | ||||||
| Phase 4 | NCT03781050 | Sep 2018 → Jan 2022 | Peutz-Jeghers syndrome | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03767660 | Jul 2018 → Jan 2022 | blue rubber bleb nevus, vascular malformation | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03500367 | Jan 2018 → Jun 2022 | leiomyoma | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00123331 | Oct 2003 → Apr 2005 | kidney failure | Heidelberg University | Completed | No outcome recorded |
| Phase 4 | NCT00290069 | — | kidney disorder, transplant rejection | Sociedad Andaluza de Trasplantes de Organos y Tejidos | Unknown | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT05233722 | Feb 2022 → Jun 2029 expected | — | University of Copenhagen | Recruiting | No outcome recorded |
| — | NCT02551718 | Sep 2015 → Jun 2020 | acute leukemia of ambiguous lineage, acute lymphoblastic leukemia | University of Washington | Completed | No outcome recorded |
| — | NCT02675153 | Apr 2015 → Oct 2020 | Crohn disease | The Second Hospital of Nanjing Medical University | Unknown | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT07689942 | — | classic familial adenomatous polyposis | Biodexa Pharmaceuticals | Available | No outcome recorded |
| Comparator or background therapy25 trials | ||||||
| Phase 0 | NCT04608448 Comparator | Apr 2021 → Apr 2022 | — | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 1 | NCT05105152 Background | Nov 2021 → Feb 2028 expected | acute myeloid leukemia | Seattle Children's Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT03732248 Comparator | Jul 2018 → Dec 2019 | alcohol dependence | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 1 | NCT02240407 Background | Oct 2017 → Aug 2021 | glycogen storage disease II | University of Florida | Completed | No outcome recorded |
| Phase 1 | NCT02048384 Comparator | Jun 2014 → Feb 2018 | pancreatic adenocarcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 1 | NCT03963024 Background | Feb 2014 → Jan 2019 | acute leukemia, bone marrow disorder, graft versus host disease, plasma cell myeloma | IRCCS San Raffaele | Terminated | No outcome recorded |
| Phase 1 | NCT02724332 Comparator | Nov 2012 → Jun 2015 | hepatocellular carcinoma | Eastern Hepatobiliary Surgery Hospital | Completed | No outcome recorded |
| Phase 1 | NCT00891696 Comparator | Apr 2009 → Mar 2015 | muscular atrophy | The University of Texas Medical Branch, Galveston | Completed | No outcome recorded |
| Phase 1 | NCT00874562 Comparator | Jul 2007 → Nov 2009 | acute lymphoblastic leukemia | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT04482712 Comparator | Apr 2021 → Jan 2022 | COVID-19, acute respiratory distress syndrome | The University of Texas Health Science Center at San Antonio | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT01346085 Background | Oct 2006 → Jun 2009 | type 1 diabetes mellitus | Ospedale San Raffaele | Completed | No outcome recorded |
| Phase 2 | NCT05342519 Comparator | Jul 2022 → Dec 2027 expected | vitiligo | Medical University of South Carolina | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04629495 Comparator | Aug 2021 → Mar 2026 overdue | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | The University of Texas Health Science Center at San Antonio | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04375813 Comparator | Jan 2021 → Jan 2027 expected | non-invasive bladder urothelial carcinoma | Robert Svatek | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03359538 Comparator | Sep 2017 → Dec 2020 | amyotrophic lateral sclerosis | University Hospital of Modena | Completed | No outcome recorded |
| Phase 2 | NCT01903473 Comparator | Jul 2013 → Sep 2022 | acute graft versus host disease, chronic graft versus host disease | University of Liege | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01526356 Comparator | May 2012 → Aug 2014 | tuberous sclerosis, vascular neoplasm | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 2 | NCT00803010 Comparator | Sep 2008 → Dec 2012 | acute graft versus host disease | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT00304954 Comparator | Feb 2006 → Jan 2010 | age-related macular degeneration, choroidal neovascularization | National Eye Institute (NEI) | Completed | No outcome recorded |
| Phase 3 | NCT05180708 Comparator | Nov 2021 → Jun 2023 | pachyonychia congenita | Palvella Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03298958 Comparator | Nov 2018 → Feb 2022 | urinary bladder cancer | The University of Texas Health Science Center at San Antonio | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01183247 Comparator | Jul 2008 → Jun 2010 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 4 | NCT00306397 Comparator | Jan 2005 → Jun 2008 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 4 | NCT00223678 Comparator | Jun 2000 → Oct 2009 | — | Vanderbilt University Medical Center | Completed | No outcome recorded |
| — | NCT01449955 Comparator | Aug 2008 → Jul 2010 | post-traumatic stress disorder | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
Press releases naming this drug 24 releases
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 117 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rapamycin | “The purpose of this OLT study is to investigate the safety of long term exposure and pharmacokinetics (PK) of QTORIN rapamycin 3.9% anhydrous gel or "PTX-022".” NCT05643872 ↗114“This study evaluates the safety and efficacy of PTX-022, topical rapamycin, in the treatment of adults with moderate to severe Pachyonychia Congenita.” NCT03920228 ↗ “The purpose of this research is to see if the drug rapamycin will improve the heart's ability to pump by improving your oxygen consumption.” NCT04996719 ↗ “The experimental group received rapamycin 2 mg/day orally for 24 weeks on the basis of methylprednisolone pulse therapy” NCT05532072 ↗ “Infusion with SC-DARIC33 followed by intermittent oral rapamycin administration” NCT05105152 ↗ “Oral rapamycin is given as a monotherapy at a initial dose of 0.8mg/m2” NCT04598204 ↗ “pre-Tx rapamycin treatment (0.1 mg/kg/day) for at least 30 days” NCT01346085 ↗ “Rapamycin p.o.: 4 mg/d, (target 8-15 ng/ml) (starting day -7)” NCT03963024 ↗ “subjects will take a once weekly 6 mg dose of rapamycin” NCT04994561 ↗ “0.5mg eRapa (encapsulated rapamycin) oral capsules” NCT04375813 ↗ “Pralatrexate Rapamycin Regorafenib” NCT02551718 ↗ |
| Known as | (RAPA, RapamuneR) (sirolimus) | “(RAPA, RapamuneR) (sirolimus)” NCT00795886 ↗ |
| Known as | Encapsulated Rapamycin | “The eRapa (encapsulated rapamycin) drug product consists of sub-micron rapamycin particles incorporated into poly(methyl methacrylate) polymer (Eudragit® L 100 / S 100).” NCT03618355 ↗1“Encapsulated Rapamycin (eRapa)” NCT04230499 ↗ |
| Known as | eRapa | “The eRapa (encapsulated rapamycin) drug product consists of sub-micron rapamycin particles incorporated into poly(methyl methacrylate) polymer (Eudragit® L 100 / S 100).” NCT03618355 ↗1“0.5mg eRapa (encapsulated rapamycin) oral capsules” NCT04375813 ↗ |
| Known as | PTX-022 | “The purpose of this OLT study is to investigate the safety of long term exposure and pharmacokinetics (PK) of QTORIN rapamycin 3.9% anhydrous gel or "PTX-022".” NCT05643872 ↗1“This study evaluates the safety and efficacy of PTX-022, topical rapamycin, in the treatment of adults with moderate to severe Pachyonychia Congenita.” NCT03920228 ↗ |
| Known as | QTORIN | “A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of...” NCT05180708 ↗1“QTORIN 3.9% Rapamycin Anhydrous Gel” NCT06239480 ↗ |
| Known as | RAPA | “Inhibition of the mTOR pathway by rapamycin (RAPA), an immunosuppressive drug used as adjunct therapy in preventing solid organ allograft rejection, enhances longevity in mice.” NCT02874924 ↗4“rapamycin (RAPA), a key component of the immunosuppressive regimen in clinical islet transplantation” PMID 21084848 ↗ Jul 2009 “daily 0.5-1.0 ml applications of 8% RAPA (Rapamycin) in a petrolatum vehicle” NCT04049552 ↗ “Rapamycin (RAPA)” NCT00803010 ↗ “Sirolimus, RAPA” NCT04629495 ↗ |
| Known as | Rapamune | “Rapamune® (rapamycin)” NCT02505893 ↗ |
| Known as | sirolimus | “The purpose of this study is to evaluate the side effects of sirolimus (rapamycin) given in combination with chemotherapy (Mitoxantrone + Etoposide + Cytarabine (MEC)) on high...” NCT00780104 ↗9“Rapamycin (sirolimus) is a drug that targets the mTOR (mammalian target of rapamycin) protein involved in the PI3K-Akt signalling pathway downstream of PI3K.” NCT06308445 ↗ “This new formulation, encapsulated rapamycin (sirolimus), provides a more predictable bioavailability of this drug than \[the other formulation\].” NCT03618355 ↗ “Subject will be randomized to take Sirolimus (Rapamycin) 0.5mg once daily for 2 years or until disease recurrence” NCT03298958 ↗ “Evaluate the tolerability and efficacy of sirolimus (rapamycin) in combination with low-dose aracytin” NCT00235560 ↗ “test two of these drugs, Rapamycin (Sirolimus) and Everolimus (Afinitor), in healthy older adults” NCT06658093 ↗ “Rapamycin (Sirolimus) Treatment for Amyotrophic Lateral Sclerosis” NCT03359538 ↗ “plus 1 mg of sirolimus/rapamycin” NCT01031901 ↗ “Rapamycin (sirolimus)” NCT00375245 ↗ “Sirolimus, RAPA” NCT04629495 ↗ |
| Action | Inhibit | “the mTOR inhibitor, sirolimus” PMID 21915260 ↗ Sep 2011 |
| Modality | Small molecule | “It is a macrocyclic lactone” NCT00795886 ↗ |
| Route | Oral | “2 mg by mouth daily” NCT00126672 ↗ |
| Target | MTOR | “the mTOR inhibitor, sirolimus” PMID 21915260 ↗ Sep 2011 |